Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.32 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.32 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922726 | 1.00 | HTR6 (0.36) | HTR6L3MBTL3L3MBTL1FYNCHRNA7 | |
| SCHEMBL2050198 | 1.00 | HTR6 (0.36) | HTR6L3MBTL3L3MBTL1FYNCHRNA7 | |
| SCHEMBL6923393 | 0.94 | CHRNA7 (0.34) | L3MBTL3L3MBTL1FYNCHRNA7TSHR | |
| SCHEMBL15320526 | 0.94 | CHRNA7 (0.34) | L3MBTL3L3MBTL1FYNCHRNA7TSHR | |
| SCHEMBL152183 | 0.77 | L3MBTL3 (0.33) | L3MBTL3L3MBTL1CHRNA7TSHRCASP1 | |
| SCHEMBL13497277 | 0.77 | L3MBTL3 (0.33) | L3MBTL3L3MBTL1CHRNA7TSHRCASP1 | |
| SCHEMBL132222 | 0.77 | SMN1; SMN2 (0.38) | L3MBTL3L3MBTL1TSHRCASP1 | |
| SCHEMBL130950 | 0.77 | L3MBTL3 (0.33) | L3MBTL3L3MBTL1CHRNA7TSHRCASP1 | |
| SCHEMBL18995008 | 0.75 | TDP1 (0.33) | L3MBTL3L3MBTL1CHRNA7TDP1 | |
| SCHEMBL131443 | 0.74 | CHRNA7 (0.50) | CHRNA7TSHRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | HTR6 130/4885L3MBTL3 3955/4885L3MBTL1 3622/4885 |
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | GRM5, GRIK5, GRM2 | HTR6 115/4885L3MBTL3 4354/4885L3MBTL1 4064/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | HTR6 130/4885L3MBTL3 3955/4885L3MBTL1 3622/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | HTR6 130/4885L3MBTL3 3955/4885L3MBTL1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.